shares of spero therapeutics inc spro soared 1884 in trading on thursday morning after the company signed an exclusive license agreement with glaxosmithkline gsk for its experimental antibiotic for complicated urinary tract infections speros therapy tebipenem hbr is expected to enter phase 3 clinical trials next year if approved it would offer patients an oral medication option instead of inhospital intravenous therapy the companies said spero is receiving 66 million upfront with at least 375 million in milestone payments speros stock is down 854 this year while the sp 500 spx has declined 205